| Popis: |
Perpose: Pancreatic cancer has a poor prognosis and is considered one of the most lethal tumors. ITGA2, a gene highly expressed in various tumor tissues, is a promising candidate for cancer therapy. The objective of this study is to assess the presence of ITGA2, MET and PD-L1 in pancreatic cancer, while also identifying ITGA2, CD4 and CD8 as potential survival indicators for patients suffering from this disease. Experimental Design: We examined the expression of ITGA2, MET, E-cad, PD-L1, CD4, and CD8 proteins in 62 pancreatic cancer tissue samples using multi-tissue immunofluorescence and immunohistochemistry techniques.This study examined how the protein expression of ITGA2, E-cad, and PD-L1 relate to clinicopathological features in patients diagnosed with pancreatic cancer. Additionally, the study examined the correlation between protein expression of ITGA2, CD4, and CD8 in pancreatic cancer and their relationship with clinicopathological features and prognosis. Results In our study, we observed the expression of ITGA2, E-cad, and PD-L1 in both tumor and stroma tissues of pancreatic cancer. Interestingly, the expression of E-cad and PD-L1 was higher in the stroma (average = 25.827% and average = 34.346%, respectively) compared to the tumor (average = 19.973% and average = 20.042%, respectively). Additionally, we found a positive correlation between ITGA2 and E-cad, as well as PD-L1 in the tumor region (r = 0.55, P 0.05).the study found that the protein expression of ITGA2 was negatively correlated with CD4 and CD8 (r = -0.344, P |
